rabeprazole has been researched along with Eosinophilic Esophagitis in 4 studies
Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
Eosinophilic Esophagitis: Chronic ESOPHAGITIS characterized by esophageal mucosal EOSINOPHILIA. It is diagnosed when an increase in EOSINOPHILS are present over the entire esophagus. The reflux symptoms fail to respond to PROTON PUMP INHIBITORS treatment, unlike in GASTROESOPHAGEAL REFLUX DISEASE. The symptoms are associated with IgE-mediated hypersensitivity to food or inhalant allergens.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This unique case with serial endoscopy and histology at baseline and monthly suggests the current recommendation of at least two months therapy with PPIs dosed twice daily is appropriate." | 1.43 | Case report of proton pump inhibitor responsive esophageal eosinophilia: why 2 months of proton pump inhibitors is required. ( Champeaux, A; Lipka, S; Muhammad, A; Richter, JE, 2016) |
| "Despite consensus recommendations, eosinophilic esophagitis (EoE) is commonly diagnosed upon esophageal eosinophilic infiltration (EEI; based on ≥ 15 eosinophils per high power field; eo/HPF)." | 1.37 | Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. ( Dueñas, C; Fernandez-Bermejo, M; Fernandez-Gonzalez, N; Ferrando-Lamana, L; Gonzalez-Nuñez, MA; Hernandez-Alonso, M; Mateos, JM; Molina-Infante, J; Quintana, EM; Ripoll, C, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lipka, S | 1 |
| Muhammad, A | 1 |
| Champeaux, A | 1 |
| Richter, JE | 1 |
| Molina-Infante, J | 2 |
| Ferrando-Lamana, L | 2 |
| Ripoll, C | 1 |
| Hernandez-Alonso, M | 1 |
| Mateos, JM | 1 |
| Fernandez-Bermejo, M | 1 |
| Dueñas, C | 1 |
| Fernandez-Gonzalez, N | 1 |
| Quintana, EM | 1 |
| Gonzalez-Nuñez, MA | 1 |
| Hirano, I | 1 |
| Vinagre-Rodriguez, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)[NCT04149470] | Phase 4 | 90 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for rabeprazole and Eosinophilic Esophagitis
| Article | Year |
|---|---|
Case report of proton pump inhibitor responsive esophageal eosinophilia: why 2 months of proton pump inhibitors is required.
Topics: Adult; Dilatation; Eosinophilic Esophagitis; Esophageal Stenosis; Esophagoscopy; Female; Humans; Nar | 2016 |
Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bi | 2011 |
Eosinophilic esophagitis and gastroesophageal reflux disease: there and back again.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Eosinophilic Esophagitis; Esophageal pH Monitoring; Gastroe | 2011 |
Esophageal hyperkeratosis after proton pump inhibitor therapy in a patient with esophageal eosinophilia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Eosinophilic Esophagitis; Esophageal Diseases; Esophagoscop | 2013 |